Source: Pharmacy Times articles
Sanofi’s SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.
Recent Content
- The long non-coding RNA CRNDE stabilises SIRT1 protein and influences Hedgehog signalling in multiple myeloma
- What Does Multiple Myeloma Mean?
- FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma
- Bone Marrow Microenvironments Vary Widely in Multiple Myeloma, Study Finds
- Safety and efficacy of BCMA CAR-T vs. bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
- Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma
- Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’
- Future Perspectives in Multiple Myeloma
- Patients and Caregivers Aim to Raise Funds for Myeloma Research